Pneumococcal

The 22F and 33F serotypes, which are associated with high rates of invasiveness and antibiotic resistance, are unique to the pneumococcal 15-valent conjugate vaccine.

Although it is the most common hospital-acquired infection, hospitals are not required to report non-ventilator-associated hospital-acquired pneumonia to the CDC National Healthcare Safety Network.

The investigators said that although pneumococcal vaccines were known to reduce severe cases of childhood pneumonia, no studies from Asia had measured their efficacy until now.

The vaccine includes all 13 serotypes in the Prevnar 13 vaccine, as well as conjugates for 7 additional serotypes associated with high case-fatality rates, antibiotic resistance, and meningitis.

The antibiotic fights both resistant enterococcus, streptococcus, and staphylococcus bacteria via a unique mechanism of action, which causes resistance to develop at a very slow pace.

Empiric anti-MRSA therapy is an area of opportunity for antimicrobial stewardship in the treatment of CAP.

Macrophages could be critical treatment targets because they could be infected by SARS-CoV-2 and can contribute to spreading the infection through the lung.

The FDA will review a Biologics License Application for V114, Merck’s investigational 15-valent pneumococcal conjugate vaccine, for the prevention of invasive pneumococcal disease.

The objective of the study was to develop a method for de-escalation of intravenous (IV) vancomycin in patients receiving vancomycin with at least 1 other antibiotic appropriate for the treatment of community-acquired pneumonia (CAP).

Cefiderocol approved for the treatment with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.

Two phase 3 studies showed an investigational 15-valent pneumococcal conjugate vaccine (V114, Merck) was well-tolerated among patients and met the primary immunogenicity objectives.

Overtreatment of acute cough can help reduce antibiotic use.

Patients can be aided by health care providers with preventable measures to reduce the chance of infectious risk.

Results from 2 initial phase 3 studies evaluating an investigational 15-valent pneumococcal conjugate vaccine were recently released, assessing its immunogenicity, safety, and tolerability.

The combination of imipenem-cilastatin and relebactam was previously approved by the FDA to treat patients with complicated urinary tract infections and complicated intra-abdominal infections who have limited or no alternative treatment options.

This will be the first global study of tocilizumab in this setting and is expected to begin enrolling in early April, with a target of approximately 330 patients globally.

The FDA has approved Xenleta (Lefamulin, from Nabriva Therapeutics) for the treatment of adults with community-acquired bacterial pneumonia (CABP) caused by susceptible microorganisms.

Pharmacists play a critical role in protecting patients from seasonal influenza and pneumonia illnesses and sequelae.

These 5 developments, including epidemic forecasting and inhaled antibiotics to treat pneumonia, have global research behind them.

The NFID released data that revealed only 52% of adults in the country plan to get vaccinated against the flu this season.

What is causing the oliguria in this normally healthy young man with a history of acne and a current sinus infection?

Meningitis is a deadly condition that affects up to 1 million people per year globally.1

According to the World Health Organization, 240 vaccines were in development for 25 infectious diseases.5 Topping the list for most candidate vac- cines are HIV/AIDS, malaria, pneumococcal infec- tions, tuberculosis, and Ebola.